US3891755A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Dosage formulation for erythromycin cetyl sulfate
Assignee: Abbott Laboratories
•
Filing: 1974-05-20
•
Granted: 1975-06-24
•
Expires: 1994-05-20
Abstract
Abstract A new tableting formulation is described for erythromycin antibiotic formulations which produce, upon ingestion, surprisingly high blood levels regardless of whether the tablet is administered to fasting or nonfasting subjects. The new formulation contains magnesium hydroxide as a major tablet component together with the usual generally accepted excipients used in elegant tablet formulations.
Inventors
- 👤 Shashi Pal Mehta
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 04:33
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/70; A61K9/00; A61K9/20; A61K9/2004; A61K9/2009
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
77 words
The process of preparing pharmaceutical tablets producing high blood levels of erythromycin, comprising uniformly blending 4 parts of an aliphatic carboxylic or sulfate salt of erythromycin with 0.5 - 6 parts of magnesium hydroxide, uniformly blending said mixture with 0.25 - 6 parts of a binder, granulating this mixture in known fashion, drying the granules, uniformly blending the granules with minor optional portions of a lubricant and other commonly used excipients and compressing this mixture into tablets.
Claim 2
Dependent Claim
77 words
The process of preparing pharmaceutical tablets producing high blood levels of erythromycin, comprising uniformly blending 4 parts of an aliphatic carboxylic or sulfate salt of erythromycin with 0.5 - 6 parts of magnesium hydroxide, uniformly blending said mixture with 0.25 - 6 parts of a binder, granulating this mixture in known fashion, drying the granules, uniformly blending the granules with minor optional portions of a lubricant and other commonly used excipients and compressing this mixture into tablets.
Claim 3
Dependent Claim
13 words
The process of claim 1 wherein said erythromycin salt is erythromycin cetyl sulfate.
Claim 4
Dependent Claim
12 words
The process of claim 1 wherein said erythromycin salt is erythromycin stearate.
Claim 5
Dependent Claim
51 words
A pharmaceutical tablet which, upon ingestion, produces a high blood level of erythromycin, comprising as the active ingredient a salt between erythromycin and an aliphatic sulfate or an aliphatic carboxylic acid and between 0.25 and 1.5 parts of magnesium hydroxide per part of said salt, and the commonly used tableting excipients.
Claim 6
Dependent Claim
51 words
A pharmaceutical tablet which, upon ingestion, produces a high blood level of erythromycin, comprising as the active ingredient a salt between erythromycin and an aliphatic sulfate or an aliphatic carboxylic acid and between 0.25 and 1.5 parts of magnesium hydroxide per part of said salt, and the commonly used tableting excipients.
Claim 7
Dependent Claim
14 words
A tablet according to claim 4 wherein said tableting excipients primarily consist of starch.
Claim 8
Dependent Claim
27 words
A tablet according to claim 5 wherein said starch is present in an amount of between 0.5 and 1.5 parts per part of said salt of erythromycin.
Claim 9
Dependent Claim
15 words
A tablet according to claim 6 wherein said salt of erythromycin is erythromycin cetyl sulfate.
Claim 10
Dependent Claim
41 words
A tablet according to claim 7 wherein the magnesium hydroxide is present in an amount of between 0.25 and 1.5 parts and the starch is present in an amount of from 0.5 to 1.5 parts per part of erythromycin cetyl sulfate.
Claim 11
Dependent Claim
14 words
A tablet according to claim 6 wherein sAid salt of erythromycin is erythromycin stearate.
Claim 12
Dependent Claim
40 words
A tablet according to claim 9 wherein the magnesium hydroxide is present in an amount of between 0.25 and 1.5 parts and the starch is present in an amount of from 0.5 to 1.5 parts per part of erythromycin stearate.
References Cited (Backward Citations)
US1889366A
Cited
US1831409A
Cited
US1694341A
Cited
US2918405A
Cited
US3060086A
Cited
US3137619A
Cited
US3352752A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1978-06-23 | 1978-12-23 | 1979-06-24 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1982-06-23 | 1982-12-23 | 1983-06-24 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1986-06-23 | 1986-12-23 | 1987-06-24 | $7700.00 | Window Closed / Lapsed |